Skip to main content

CARE T cells

Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors

  • RegistryNCT04715191
  • PhasePhase 1
  • StatusRecruiting
  • ConditionLiver Cancer
  • SponsorBaylor College of Medicine
How CARE T cells worksNCT047151911 min

What the film says

Read the transcript

Some childhood solid tumors, liver cancer, rhabdomyosarcoma, Wilms tumor, share a surface protein called glypican-3. When those cancers return after surgery and chemotherapy, cures are rare.

The idea: aim engineered T cells at that shared protein, and arm them so they survive inside a solid tumor.

CAR T cells often stall in solid tumors, where they run out of support. At Texas Children's, a child's T cells receive a receptor for glypican-3 plus genes for two growth signals, interleukin-15 and interleukin-21, so the cells carry their own fuel. After three days of chemotherapy makes room, they are infused once.

A dose-finding trial, ages one to twenty-one, for tumors that test positive for the protein. David Steffin leads it. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04715191

    GPC3 on pediatric liver cancer, rhabdomyosarcoma, Wilms, rhabdoid, yolk sac tumors; Relapsed / refractory / cannot receive standard treatment; CAR T stall in solid tumors — general framing; GPC3 CAR + IL-15 + IL-21 ("CARE T cells") (+2 more lines)

The drug

What is being tested.

Four different dosing schedules will be evaluated. The following dose levels will be evaluated: DL0: 1x10^7/m^2 DL1: 3x10^7/m^2 DL2: 1x10^8/m^2 DL3: 3x10^8/m^2 The doses are calculated according to the actual number of GPC3-CAR transduced T cells.

Approximately 18-30 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (not exceeding 3ml/kg/day) is collected from patients to grow the T cells and a retrovirus (a special virus that can insert the GPC3 CAR gene into the T cells) is used to genetically engineer them. After the CAR gene was put into the T cells, the investigators make sure that they are able to kill GPC3 positive solid tumor cells in the laboratory.

LYMPHODEPLETION CHEMOTHERAPY: Several studies suggest that the infused T cells need room to be able to increase in numbers/multiply and accomplish their functions and that this may not happen if there are too many other T cells in circulation . Because of that, participants will receive treatment with lymphodepletion chemotherapy. This chemotherapy means the participant will receive both cyclophosphamide (Cytoxan) and fludarabine.

The study

How the trial runs.

Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called CARE T cells, a new experimental treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells.

Antibodies are types of proteins that protect the body from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. Both antibodies and T cells have been used to treat patients with cancers. They have shown promise, but have not been strong enough to cure most patients.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Procurement Eligibility
  • Diagnosis of GPC3-positive* solid tumors (as determined by immunohistochemistry with an extent score of >=Grade 2 [>25% positive tumor cells] and an intensity score of >= 2 [scale 0-4]).
  • Age ≥1 year and ≤ 21 years
  • Lansky or Karnofsky score ≥60%
  • Life expectancy ≥16 weeks
  • Barcelona Clinic Liver Cancer Stage A, B or C (for patients with hepatocellular carcinoma only)

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.